Search

Merck & Co Inc.

Gesloten

SectorGezondheidszorg

150.28 -1.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

150.06

Max

150.81

Belangrijke statistieken

By Trading Economics

Inkomsten

2.9B

-1.3B

Verkoop

321M

17B

K/W

Sectorgemiddelde

119.161

56.659

EPS

-0.13

Dividendrendement

2.24

Winstmarge

-8.051

Werknemers

73,000

EBITDA

3.4B

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+3.03% upside

Dividenden

By Acuity

Dividendrendement

Sectorgemiddelde

2.24%

2.18%

Volgende Winsten

29 okt 2026

Volgende dividenddatum

7 okt 2026

Volgende Ex Dividend datum

15 sep 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

57B

365B

Vorige openingsprijs

151.59

Vorige sluitingsprijs

150.28

Nieuwssentiment

By Acuity

44%

56%

135 / 339 Rangschikking in Healthcare

Merck & Co Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 sep 2026, 23:05 UTC

Merck & Co Inc shares are higher in after-market trading, despite no specific news. Broader market signals show mixed economic indicators and rising Treasury yields.

3 sep 2026, 23:05 UTC

Merck & Co Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid broader market gains.

2 sep 2026, 19:46 UTC

Social Media
News

Merck & Co Inc is rising following positive results from the ATLAS-UC Phase 3 trial, which met its primary endpoint of clinical significance.

1 sep 2026, 23:07 UTC

Merck & Co Inc. shares were roughly flat during after-market hours, with no specific company news identified amid broader market fluctuations driven by rising oil prices.

31 aug 2026, 23:16 UTC

Merck & Co Inc shares are trading higher in after-market hours. Broader market sentiment is influenced by escalating geopolitical tensions and inflation concerns.

28 aug 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market trading, supported by rising Treasury yields and trading above their 20-day moving average.

27 aug 2026, 23:01 UTC

Merck & Co Inc. shares are higher in after-market trading, reflecting routine performance despite three consecutive lower sessions. The stock remains above its 20-day moving average.

26 aug 2026, 23:11 UTC

Merck & Co Inc is higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 aug 2026, 23:06 UTC

Social Media

Merck & Co Inc reached all-time highs in after-market trading, gaining over $6 amid positive social media sentiment and broader market dynamics.

24 aug 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market trading, showing stable performance since Monday's close. The stock remains above its 20-day moving average.

21 aug 2026, 19:31 UTC

News
Social Media

Merck & Co Inc shares are higher today as Goldman Sachs and Morgan Stanley upgraded their ratings and raised price targets, citing confidence in cancer treatments.

20 aug 2026, 19:31 UTC

News
Social Media
Event

Merck & Co Inc shares are lower today following downgrades from RBC Capital and UBS, with both firms setting a price target of $150.

19 aug 2026, 23:41 UTC

Event
Social Media

Merck & Co Inc shares declined in after-market trading despite positive Phase 3 trial results for its mRNA-based therapy combined with KEYTRUDA.

17 aug 2026, 19:36 UTC

News

Merck & Co Inc shares are higher during Monday's session, reflecting a slight cumulative return since Friday's close amid rising long-term Treasury yields.

15 aug 2026, 00:01 UTC

Merck & Co Inc shares are lower in after-market hours following notable volatility during the session, despite mixed global market performance.

14 aug 2026, 23:21 UTC

Merck & Co Inc shares are lower in after-market trading following a decline in U.S. retail sales for July, raising concerns about consumer demand.

13 aug 2026, 23:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours, remaining above their 20-day moving average after three consecutive sessions of higher finishes.

12 aug 2026, 19:56 UTC

News

Daiwa Capital upgraded Merck to Outperform, raising the price target to $143. The stock remains higher since Tuesday's close amid positive FDA news.

11 aug 2026, 19:36 UTC

News

Merck & Co. shares are lower today despite Argus Research maintaining a Buy rating and raising the price target to $145.

10 aug 2026, 19:36 UTC

Social Media
News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7 aug 2026, 22:06 UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6 aug 2026, 23:01 UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5 aug 2026, 19:43 UTC

News
Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4 aug 2026, 23:26 UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3 aug 2026, 20:03 UTC

News
Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31 jul 2026, 23:16 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30 jul 2026, 20:09 UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29 jul 2026, 23:41 UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28 jul 2026, 23:01 UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27 jul 2026, 20:06 UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

Peer Vergelijking

Prijswijziging

Merck & Co Inc. Prognose

Koersdoel

By TipRanks

3.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 154.88 USD  3.03%

Hoogste 180 USD

Laagste 105 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck & Co Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

13

Buy

4

Hold

0

Sell

Sentiment

By Acuity

135 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
help-icon Live chat